A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection

AIDS

Volumn 12, Issue 5, 1998, Pages

  Mooij, Petra ^a   Van Der Kolk, Mike ^a   Bogers, Willy M J M ^a   Ten Haaft, Peter J F ^a   Van Der Meide, Peter ^a   Almond, Neil ^b   Stott, Jim ^b   Deschamps, Marguerite ^c   Labbe, Dominique ^c   Momin, Patricia ^c   Voss, Gerald ^c   Von Hoegen, Paul ^c   Bruck, Claudine ^c   Heeney, Jonathan L ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Chimeric simian human immunodeficiency virus; HIV 1 recombinant gp120; Protection; Rhesus macaque; Vaccine

Indexed keywords

CHEMOKINE RECEPTOR; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE;

AIDS VACCINES; ANIMALS; ANTIBODY AFFINITY; CHIMERA; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; IMMUNITY, CELLULAR; MACACA MULATTA; NEUTRALIZATION TESTS; POLYMERASE CHAIN REACTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINES, SYNTHETIC;

EID: 15444345624     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199805000-00002     Document Type: Article

References (31)

1. Lamptey P, Tarantola D, Ankrah EM, et al.: Final report: the status and trends of the global HIV/AIDS pandemic. Presented at the XI International Conference on AIDS. Vancouver, July 1996.
2. Heeney JL, Bruck C, Goudsmit J, et al.: Immune correlates of protection to HIV infection and AIDS. Immunol Today 1997, 18:4-8.
3. Bloom BR: A perspective on AIDS vaccines. Science 1996, 272:1888-1890.
4. Heeney JL: Primate models for AIDS vaccine development. AIDS 1996, 10(suppl A):S115-S122.
5. Berman PW, Gregory TJ, Riddle L, et al.: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990, 345:622-625.
6. Girard M, Kieny MP, Pinter A, et al.: Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 1991, 88:542-546.
7. Bruck C, Thiriart C, Fabry L, et al.: HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 1994, 12:1141-1148.
8. Li J, Lord CI, Haseltine W, Letvin NL, Sodroski J: Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr 1992, 5:639-646.
9. Luciw PA, Pratt-Lowe E, Shaw KE, Levy JA, Cheng-Mayer C: Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci USA 1995, 92:7490-7494.
10. Groenink M, Fouchier RA, de Goede RE, et al.: Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J Virol 1991, 65:1968-1975.
11. Stoute JA, Slaoui M, Heppner DG, et al.: A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997, 336:86-91.
12. van der Meide PH, Groenestein RJ, de Labie MC, Heeney J, Pala P, Slaoui M: Enumeration of lymphokine-secreting cells as a quantitative measure for cellular immune responses in rhesus macaques. J Med Primatol 1995, 24:271-281.
13. Heeney JL, van Els C, de Vries P, et al.: Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells. J Exp Med 1994, 180:769-774.
14. Hedman K, Rousseau SA: Measurement of avidity of specific IgG for verification of recent primary rubella. J Med Virol 1989, 27:288-292.
15. Weber J, Fenyo E, Beddows S, Kaleebu P, Bjorndal A: Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. J Virol 1996, 70:7827-7832.
16. Glantz SA: Primer of Biostatistics [Medical Statistics Series]. Edited by Kaufman B, White B, White J. Singapore: McGraw-Hill International Editions; 1989:64-325.
17. Ranjbar S, Jones S, Stott EJ, Almond N: The construction and evaluation of SIV/HIV chimaeras which express the envelope of European HIV-1 isolates. AIDS Res Hum Retroviruses 1997, 12:797-805.
18. Groenink M, Andeweg AC, Fouchier RA, et al.: Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. J Virol 1992, 66:6175-6180.
19. Bogers WMJM, Dubbes R, ten Haaft P, et al.: Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta. Virology 1997, 236:110-117.
20. Bogers WMJM, Niphuis H, ten Haaft P, Laman JD, Koornstra W, Heeney JL: Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge. AIDS 1995, 9:F13-F18.
21. Bontrop RE, Otting N, Niphuis H, Noort R, Teeuwsen V, Heeney JL: The role of major histocompatibility complex polymorphisms on SIV infection in rhesus macaques. Immunol Lett 1996, 51:35-38.
22. Baskin CB, Bontrop RE, Niphuis H, Rice J, Heeney JL: Correlation of major histocompatibility complex with opportunistic infections in simian immunodeficiency virus-infected rhesus monkeys. Lab Invest 1997, 77:305-309.
23. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258:1938-1941.
24. Heeney JL, Holterman L, ten Haaft P, et al.: Vaccine protection and reduced virus load from heterologous macaque propagated SIV challenge. AIDS Res Hum Retroviruses 1994, 10 (suppl 2):S117-S121.
25. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM: Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995, 267:1820-1825.
26. Trkola A, Dragic T, Arthos J, et al.: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384:184-187.
27. Mustafa F, Richmond JF, Fernandez-Larsson R, et al.: HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity. Virology 1997, 229:269-278.
28. Joag SV, Li Z, Foresman L, et al.: Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. J Virol 1996, 70:3189-3197.
29. Reimann KA, Li JT, Voss G, et al.: An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol 1996, 70:3198-3206.
30. Reimann K, Li, JT, Veazey, R, et al.: A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996, 70:6922-6928.
31. Stephens E, Joag SV, Sheffer D, et al.: Initial characterization of viral sequences from a SHIV-inoculated pig-tailed macaque that developed AIDS. J Med Primatol 1996, 25:175-185.